A Study Has Revealed The Biggest Risk Factors For Getting Early Dementia, And Knowledge Is Power

A recent study by the University of Exeter and Maastricht University published in JAMA Neurology has identified some of the factors that can lead to early cases of dementia ― some of which may surprise you.
The data analyzed the behaviors of over 350,000 participants younger than 65 across the United Kingdom to evaluate young-onset dementia, which occurs before age 65. The researchers found there are 15 common issues that can contribute to the early development of the condition. A few have to do with genetics and other elements outside our control, but many others are modifiable.
The study is meaningful to experts because it 'looks at young-onset dementia risk factors in a way that has only been done in late-onset dementias previously,' according to Dr. Kevin Bickart, an assistant professor in neurology at the University of California Los Angeles Health's David Geffen School of Medicine. The study features 'a very large sample that was prospectively followed from healthy baseline to a dementia diagnosis with lots of data collection.'
Here's what to know:
The biggest risk factors for young-onset dementia:
Related: "This Has Taken Me Years And Years And YEARS To Figure Out": This Woman's Clever Way To Tell If Someone Is Your Real Friend Is Being Called The Most Accurate Thing Ever
Related: 25 Eye-Opening Confessions From A Trauma Therapist That Changed The Way I Think About Mental Health
The large-scale study looked at 39 possible risk factors and determined that 15 of them made the biggest difference when it came to developing dementia before the age of 65. Those include:
Social isolation
Lower formal education
Lower socioeconomic status
Carrying two copies of the APOE gene (a marker that influences Alzheimer's risk)
Vitamin D deficiency
Hearing impairment
Alcohol use disorder
No alcohol use (abstinence)
Depression
High C-reactive protein levels
Lower handgrip strength (physical frailty)
Orthostatic hypotension (a form of low blood pressure)
Stroke
Diabetes
Heart disease
Although some recognized risks are out of many people's control ― like being a carrier of the APOE gene or your socioeconomic status ― others can be managed through lifestyle changes.
What you can do to lower your risk of early-onset dementia.
Overall, the study results are consistent with what medical experts have been advising patients for years.
Dr. Arman Fesharaki-Zadeh, an assistant professor of psychiatry and of neurology at the Yale School of Medicine, recommended three 'lifestyle measures' that folks may want to consider when trying to lower their risk of young-onset dementia ― starting with physical exercise.
'An active daily exercise practice can have far-reaching benefits, which include enhanced neurocognitive function,' Fesharaki-Zadeh said, adding that physical activity can boost neurogenesis (the formation of new neurons and synapses), vasculogenesis (the creation of new blood vessels) while also providing inherent mood benefits.
Next, focus on eating nourishing foods. Fesharaki-Zadeh championed a Mediterranean-based diet, mentioning its well-documented benefits.
'Such dietary practice, which includes food groups such as green leafy vegetables, olive oil, salmon and blueberries, is rich in vitamins, omega-3 fatty acids, as well as antioxidants ― all neuroprotective factors,' he explained.
Fesharaki-Zadeh recommended cognitive, mood and social stimulation to keep your mind sharp.
For cognitive stimulation, this could look like learning a new language or attending a seminar, listening to music or dancing. Basically, anything that engages your mind will help it stay healthy. Mood stimulation, on the other hand, relates to stress reduction practices, 'such as mindfulness and yoga,' Fesharaki-Zadeh said.
As for social stimulation, it's pretty simple: Try to connect with other humans face-to-face and actually talk to them as much as possible. 'In the era of pandemic and now post-pandemic, quality social connections should increasingly be encouraged and practiced,' Fesharaki-Zadeh said.
While these habits don't cover the whole list of dementia risk factors, they are a pretty solid start.This article originally appeared on HuffPost.
Also in Goodful: Therapists Are Revealing The Moments That Made Them Break Their "No Judgment" Rule, And I'm Honestly Speechless
Also in Goodful: 19 "Garbage" Modern Trends People Refuse To Partake In Despite Their Popularity
Also in Goodful: Medical Professionals Are Sharing "Mundane" Things That Actually Make So Many People Sick

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

David Hopkinson obituary

My friend and former colleague David Hopkinson, who has died aged 89, was director of the Medical Research Council's human biochemical genetics unit at University College London from 1976 until its closure in 2000. Hoppy, as he was universally known, had joined the unit at its inception in 1962 because in an earlier, more junior, position he had been one of the first medical scientists to describe molecular differences in human enzymes, long before DNA sequence differences were known about. The unit was established to research the extent and significance of genetic variation to human health. As its head, Hoppy expanded its focus to gene mapping and disease genetics while also moving into the new science of gene cloning and DNA sequencing. Born in Chesterfield, Derbyshire, to Albert Hopkinson, an iron and steelworks foreman, and Lilian (nee Siddal), a dressmaker, he went to Chesterfield grammar school, which fostered his early interest in organic chemistry. After completing a natural sciences degree at Cambridge University he qualified in medicine at the London hospital in 1959, working there until he joined the human biochemical genetics unit three years later. Hoppy was recruited by its inaugural head, Prof Harry Harris, becoming his right-hand man responsible for many of the unit's innovative experimental approaches, including developing novel methods of enzyme detection and electrophoresis. The unit moved in 1965 from its initial base at King's College to UCL, where I joined the unit three years later to study for a PhD under Harris. Hoppy remained there for the rest of his career. He published widely, and played an important part in teaching and supervision, being made full professor of London University in 1990. Twenty five years after his retirement, his role as mentor is remembered with great warmth by his former staff and students. Hoppy read widely and appreciated drama and music. A practical man who took pleasure in manual labour, he was an accomplished gardener and delighted in propagating plants and growing vegetables. He also enjoyed summers hiking in the Swiss Alps, and was a keen birdwatcher. In retirement, he studied architecture and German, and gained a first-class degree in geology at the Open University. He also spent many years as a volunteer at Chilterns' Citizens Advice in Chesham, Buckinghamshire. He is survived by his second wife, Prof Yvonne Edwards, and by three children, Paul, Susan and Ian, from his first marriage, to Josephine (nee Manze), which ended in divorce, and four grandchildren.

Yahoo

2 hours ago

• Yahoo

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Bloomberg

3 hours ago

• Bloomberg

UK Heat Wave Could Claim Nearly 600 Lives This Week, Experts Warn

Scientists have warned the elderly and other vulnerable groups in the UK are at risk of heat-related deaths this weekend, as a new study shows recent high temperatures could claim 570 lives in just over four days. Researchers at the London School of Hygiene & Tropical Medicine and Imperial College London published on Saturday a real-time analysis calculating the number of heat-related deaths expected from Thursday to Sunday.